Equities analysts expect that Concert Pharmaceuticals Inc (NASDAQ:CNCE) will report ($0.18) earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for Concert Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.17 and the lowest estimate coming in at ($0.53). Concert Pharmaceuticals posted earnings of ($0.54) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 66.7%. The firm is expected to announce its next quarterly earnings report on Monday, March 5th.

On average, analysts expect that Concert Pharmaceuticals will report full year earnings of $4.10 per share for the current year, with EPS estimates ranging from $3.64 to $4.55. For the next fiscal year, analysts expect that the business will post earnings of ($2.35) per share, with EPS estimates ranging from ($2.39) to ($2.31). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that cover Concert Pharmaceuticals.

Several research analysts have commented on the stock. Zacks Investment Research cut shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, September 15th. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of Concert Pharmaceuticals in a report on Friday, October 20th. Stifel Nicolaus reiterated a “buy” rating and set a $30.00 price target on shares of Concert Pharmaceuticals in a report on Sunday, October 22nd. Finally, Mizuho assumed coverage on shares of Concert Pharmaceuticals in a report on Thursday, October 26th. They set a “buy” rating and a $23.00 price target for the company. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $23.00.

Concert Pharmaceuticals (NASDAQ CNCE) traded up $0.93 during midday trading on Monday, reaching $27.55. 375,204 shares of the company’s stock traded hands, compared to its average volume of 255,689. Concert Pharmaceuticals has a 12 month low of $8.48 and a 12 month high of $27.91.

In related news, insider Value Fund L. P. Biotechnology acquired 331,916 shares of Concert Pharmaceuticals stock in a transaction dated Thursday, October 19th. The stock was acquired at an average price of $15.84 per share, for a total transaction of $5,257,549.44. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ronald W. Barrett sold 14,156 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $24.70, for a total transaction of $349,653.20. Following the sale, the director now owns 3,539 shares of the company’s stock, valued at approximately $87,413.30. The disclosure for this sale can be found here. 10.10% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company lifted its position in shares of Concert Pharmaceuticals by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock worth $210,000 after buying an additional 287 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Concert Pharmaceuticals by 0.6% during the 1st quarter. Geode Capital Management LLC now owns 142,740 shares of the biotechnology company’s stock worth $2,435,000 after buying an additional 838 shares during the last quarter. Alps Advisors Inc. lifted its position in shares of Concert Pharmaceuticals by 6.3% during the 2nd quarter. Alps Advisors Inc. now owns 20,362 shares of the biotechnology company’s stock worth $284,000 after buying an additional 1,200 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Concert Pharmaceuticals by 8.0% during the 2nd quarter. Rhumbline Advisers now owns 20,253 shares of the biotechnology company’s stock worth $283,000 after buying an additional 1,500 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Concert Pharmaceuticals by 1.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 125,996 shares of the biotechnology company’s stock worth $1,757,000 after buying an additional 1,852 shares during the last quarter. Institutional investors and hedge funds own 65.36% of the company’s stock.

WARNING: “Concert Pharmaceuticals Inc (CNCE) Expected to Post Earnings of -$0.18 Per Share” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/concert-pharmaceuticals-inc-cnce-expected-to-post-earnings-of-0-18-per-share/1771829.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Get a free copy of the Zacks research report on Concert Pharmaceuticals (CNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.